Drug intelligence / Profile preview

tubeimoside B

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Tubeimoside B (also known as tubeimoside II) is a natural oleanane-type triterpenoid saponin isolated from the tuber of *Bolbostemma paniculatum* (a Chinese folk medicine called 'Tubeimu'). It is a small-molecule research compound exhibiting anti-inflammatory, antitumor, anti-fibrotic, and broad-spectrum antiviral activities. Tubeimoside B acts as an inhibitor of procollagen galactosyltransferase 1 (COLGALT1/GLT25D1), which blocks collagen beta(1-O) galactosylation and promotes collagen endoplasmic reticulum (ER) retention in hepatic stellate cells, triggering PERK-eIF2α-ATF4-mediated ER stress and apoptosis to attenuate hepatic fibrosis progression. Additionally, it acts as a ligand of interferon-inducible double-stranded RNA-dependent protein kinase activator A (PRKRA/PACT), activating the RIG-I signaling pathway and increasing type I interferon (IFN-β) secretion to exert broad-spectrum antiviral effects against respiratory viruses such as SARS-CoV-2 and influenza A. It is widely used as a reference substance or research reagent and is not currently developed as an approved drug by any pharmaceutical company.

Other names
Tub Btubeimoside IItubeimoside-Btubeimoside-II
02

Targets

PRKRA (Interferon-inducible double-stranded RNA-dependent protein kinase activator A)Glycosylation (Glycosylation enzymes)

Beyond the preview

Go deeper on tubeimoside B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tubeimoside B.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call